Research Collaborations & Affiliations

Mello Biotech collaborates with leaders in the field of stem cell reprogramming using microRNA and also innovative microRNA therapies. The company welcomes discussion on research collaboration opportunities to establish additional use for its proprietary products.

Christine C. Wu, Ph.D. University of Pittsburgh, School of Medicine

Dr. Wu is an Assistant Professor at the University of Pittsburg, School of Medicine. Dr. Wu is one of the nation’s innovative leaders in the frontier of proteomics, as she frequently presents the latest updates and advancements in the field. Devoting her time between teaching and research, Dr. Wu is often found giving talks at the American Society for Cell Biology and National Symposium. Before joining the University of Pittsburgh, Dr. Wu was an assistant professor at University of Colorado.  Dr. Wu also worked as a postdoctoral fellow at the Scripps Research Institute regarding the advancements in the field of Proteomics. Dr. Wu received her BS in Biochemistry at UCLA and her MS and Ph.D. degrees at the Department of Cell and Developmental Biology at the University of Colorado Health Sciences Center.

Shi-Lung Lin, Ph.D, M.T, M.S. W&L Institute

Dr. Lin is the Science Director at the W&L Institute.  Before joining the W&L Institute, Dr. Lin was an Assistant Professor of Cell and Neurobiology at the Keck School of Medicine, University of Southern California.  He has worked several NIH-funded research projects focusing on cancer mechanisms. Dr. Lin has more than ten-years of experience in the fields cancer research, biochemistry, and molecular biology.  As a pioneer in stem cell research and RNA-mediated transgene technology, Dr. Lin is the first scientist to reprogram somatic hair follicle cells into embryonic stem (ES)-like pluripotent cells.  He is also the first scientist to identify the biogenesis mechanism of intronic microRNA (miRNA).  Dr. Lin has successfully proven the usefulness of various miRNA agents in biomedical applications, in particular the therapeutic interventions for cancer therapy and generation of microRNA induced pluripotent stem cell (mirPS).  His research aims to elucidate the function and use of microRNA (miRNA) agents in disease therapy and development of new gene-modification (GM) biotechnologies using a novel transgenic animal method.  This technology is applied to produce GM plants without the risk of foreign gene insertion.  His invention is licensed to one of the largest agricultural conglomerates in the world.  Dr. Lin has published more than 40 peer-reviewed publications, 20 book chapters, and 17 patents.  He received his Ph.D. of Pathology and M.S. of Biochemistry at USC, and his undergraduate degree at Chung-Shan Medical University, Taichung, Taiwan.

Shao-Yao Ying, Ph.D USC Medical

Dr. Ying is a tenured Professor of Cell and Neurobiology at the Keck School of Medicine, University of Southern California (USC). Dr. Ying is a renowned pioneer in endocrinology and prostate cancer research. He has published over three hundred peer-reviewed journal papers and more than twelve scientific books and book chapters. Prior to joining USC, Dr. Ying was an Assistant Professor of Neuroendocrinolgy at Harvard Medical School. Dr. Ying is the first scientist who discovered and identified “Activin”, a major growth factor required for the human reproduction system and embryonic development. For this discovery, his mentor, Dr. Roger Guillemin was awarded the Nobel Prize in 1977. Currently, his research aims to elucidate the functional roles of cancer-related microRNAs (miRNAs) in prostate cancer progression and relapse. In collaboration with Dr. Shi-Lung Lin in searching novel gene targets for cancer therapy, Dr Ying have recently identified the first tumor suppressor miRNA gene, mir-146, in prostate cancer, of which the result may be useful for design and development of novel therapeutical interventions against prostate cancer progression and relapse. The same therapeutic approach may also be used to treat many other epithelial cancers, such as breast and skin cancers. Dr. Ying received his Ph.D. of Reproductive Physiology and Endrocrinlogy at the University of Wisconsin in Madison, and his B.S. of Zoology at the National Taiwan University, Taiwan.

Shiaw-Min Hwang, Ph.D. Bioresource Collection and Research Center

Dr. Hwang is a principle investigator at the Taiwan Stem Cell Bank, and at the Cell Bank of National Health Research Institute, and a senior scientist at the Bioresource Collection and Research Center (BCRC).  BCRC is the core facility of National Health Research Institute for “Cell Bank” in Taiwan. The institution is the most systematic and service-oriented bioresource center (BRC) in Asia, and has been a member of World Federation for Culture Collections (WFCC) since 1984.  Dr. Hwang received his Ph.D. of Microbiology and Molecular Genetics at the Rutgers University, USA.

Haw-Yueh (Kelly) Thong, MD NTU Hospital

Dr. Thong is a medical doctor of dermatology at the National Taiwan University Hospital.  Before practicing at NTU Hospital, Dr. Thong was a research fellow at the Department of Dermatology at UCSF under the guidance of Dr. Howard Maibach.  Dr. Thong published numerous research articles in the areas of dermatitis and cosmetic dermatology.  Dr. Thong received her MD at the National Taiwan University, and MS at Stanford University.

Applied Stem Cell

Applied StemCell Inc. (ASC) is a biotechnology company with its headquarter based in Menlo Park, California. ASC focuses on the application of new technologies for stem cell and transgenic communities.